Clinical trial
Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe…
NCT00415597 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00415597 |
|---|---|
| Title | Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain |
| Official title | A Long-Term, Open-Label Safety Study of ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects With Chronic Moderate to Severe Nonmalignant Pain |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pain |
| Intervention type | Drug |
| Interventions | ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER) |
| Enrollment | 467 |
| Start date | Dec 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Dec 25, 2006 |
| Last update posted | Sep 20, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: